| Literature DB >> 3079477 |
Abstract
Three cooperative groups are currently accruing patients to randomized Phase III studies of 5-FU plus leucovorin. These studies should provide data allowing more definitive conclusions regarding the therapeutic utility of this combination. Until results of these studies are available, 5-FU plus leucovorin (CF) remains an investigational treatment, not suitable for routine use.Entities:
Mesh:
Substances:
Year: 1987 PMID: 3079477
Source DB: PubMed Journal: Oncology (Williston Park) ISSN: 0890-9091 Impact factor: 2.990